Exelixis purchased an exclusive license for Insilico Medicine’s ISM3091 inhibitor for $80 million, outbidding at least four other companies. Insilico founder Alex Zhavoronkov selected Exelixis after being impressed by the company’s successful development of the cancer drug Cabometyx. Exelixis will also make additional payments for meeting development, commercial and sales-based milestones.
Nearly half of cyber leaders claim they’ve hidden a material cybersecurity incident from their board – IT Brew
Nearly half of cyber leaders claim they’ve hidden a material cybersecurity incident from their board IT Brew
